Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClaritevCTEV -4.75%57 EV-to-EBIT is 217.04 as of Jul. 22, 2026. GuruFocus rates CTEV with a GF Score™ of 57/100 and a GF Value™ of $31.34 (Fairly Valued). The stock has 6 warning signs investors should review. Among 468 Healthcare Providers & Services companies, Claritev ranks worse than 96.37% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Claritev's Enterprise Value is $5,208.4 Mil.
Claritev's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $24.0 Mil. Therefore, Claritev's EV-to-EBIT for today is 217.04.
The historical rank and industry rank for Claritev's EV-to-EBIT or its related term are showing as below:
CTEV'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1646.5 Med: -5.25 Max: 272.7
Current: 217.04
During the past 8 years, the highest EV-to-EBIT of Claritev was 272.70. The lowest was -1646.50. And the median was -5.25.
CTEV's EV-to-EBIT is ranked worse than 96.37% of 468
companies
in the Healthcare Providers & Services industry
Industry Median: 16.025
vs CTEV: 217.04
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Claritev's Enterprise Value for the quarter that ended in Mar. 2026 was $4,997.1 Mil.
Claritev's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Claritev EV-to-EBIT Related Terms
Claritev EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Claritev's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Claritev's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Claritev EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Claritev's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Claritev's EV-to-EBIT falls into.
Claritev's current Enterprise Value is $5,208.4 Mil.
Claritev's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Claritev (CTEV) has a EV-to-EBIT of 217.04 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Claritev and its competitors. According to the industry distribution chart, Claritev ranks #451 out of 468 companies in the Healthcare Providers & Services industry, placing it in the top 96.4%.
Is Claritev's EV-to-EBIT too high?
Claritev's current EV-to-EBIT is 217.04. The Healthcare Providers & Services industry median EV-to-EBIT is 16.03. Claritev's value of 217.04 is 1254.4% above this industry median. Based on the distribution chart, Claritev ranks #451 out of 468 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Claritev has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Claritev's EV-to-EBIT compare to MDRX and EVH?
According to the Healthcare Providers & Services industry distribution chart, Claritev ranks #451 out of 468 companies for EV-to-EBIT. This places Claritev in the lower half of its industry. The industry median EV-to-EBIT is 16.03. Claritev's value of 217.04 is 1254.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 16.03, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Claritev's current EV-to-EBIT of 217.04 is 1254.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Claritev and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 16.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Claritev's current EV-to-EBIT is 217.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Claritev stock overvalued right now?
Based on GuruFocus' analysis, Claritev (CTEV) is currently considered Fairly Valued. The stock's GF Value™ is $31.34, compared to a current price of $28.69 — trading 8.5% below its estimated fair value. The current EV-to-EBIT is 217.04 and 1254.4% above the Healthcare Providers & Services industry median of 16.03. Claritev's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Claritev (CTEV), the current EV-to-EBIT is 217.04 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Claritev (CTEV) Overvalued in 2026?
Based on GuruFocus' analysis, Claritev stock appears to be undervalued.
The current stock price of $28.69 is trading 8.5% below its estimated GF Value™ of $31.34.
GuruFocus considers Claritev to be Fairly Valued.
Key valuation signals for CTEV:
EV-to-EBIT: 217.04
GF Value™: $31.34 vs. price of $28.69 (8.5% below fair value)
Industry Position: 1254.4% above the Healthcare Providers & Services median (#451 of 468)
No single metric tells the full story. See the CTEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The company's focus is on being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
57GF Score
Get the complete analysis for CTEV
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTEV has been successfully added to your 
